On the other hand, the frequency of Lys/Gln and Gln/Gln variants of XPD was significantly higher in cancer patients having a family history of cancer compared to control (OR=3.17; 95% CI=1.20-8.39; p=0.024; OR=16.35; 95% CI=0.92-289.5; p=0.007 respectively). Here, ERCC2 is linked to cancer.